Year-End Spending Bill Sets FDA 2023 Budget At $6.6B

In addition to higher spending, the omnibus package now before the US Congress also addresses dual submissions, cybersecurity, pandemic preparedness, and more.  

US FDA with cloud dollars. photo illustration with Alamy and Shutterstock images
• Source: photo illustration/Alamy, Shutterstock images

The US Food and Drug Administration will see a major funding boost in the year-end omnibus spending bill, expected to pass Congress this week, with lawmakers allotting $6.6bn for the agency – up $226m from the 2022 budget. That includes $736.4m for the Center for Devices and Radiological Health.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

End Of The Road? Court LDT Decision May Leave FDA With Few Options

 

Now that a federal judge has ruled the US FDA exceeded its authority by unilaterally assuming regulatory oversight of lab-developed tests, what’s the agency’s next move? And does it really have one?

Medtech Industry Faces Tariffs Despite Pleas for Exemption

 
• By 

Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.

Democrats Condemn Trump’s HHS Layoffs During House Hearing On OTC Drug User Fees

 

Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.

Whitaker Wants Congress To Capitalize On ‘Golden Age Of Medical Innovation’

 

AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.

More from Policy & Regulation

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

 
• By 

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.

EU Harmonized Standards Continue To Trickle In Under MDR

 

Well over 200 European standards need harmonizing under the MDR. But only around 12% have been attended to so far.

Medtech Looks For Relief As Trump Hits Pause On Most Tariffs

 
• By 

The medtech industry hopes to use a 90-day pause on tariffs to negotiate a “zero for zero” exemption. However, recent public comments from President Donald Trump suggest the health care sector may still be at risk.